Clinical Trial Update: Efficacy and Safety of AMN107 in Patients With GastroIntestinal Stromal Tumors (GIST) Who Have Failed Both Imatinib and Sunitinib [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluates the efficacy and safety of AMN107 (nilotinib) in patients with gastrointestinal stromal tumors who progressed after imatinib and su…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumors

Drugs mentioned

• AMN107 (nilotinib) (nilotinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Gastrointestinal Stromal Tumors | Phase 2 | Status: COMPLETED